BOSTON, June 4, 2021 /PRNewswire/ — Delix Therapeutics (the “Company”), a preclinical neuroscience company developing novel disease-modifying therapeutics for serious psychiatric and neurological conditions, today announced the inaugural members of its Scientific and Strategic Advisory Board. Headquartered in Massachusetts, Delix is creating a new class of neuroplasticity-promoting therapeutics…


Previous articlePTSF62 – Senate Bill 519, Ketamine, and Psilocybin-producing Cicadas
Next articlePsychedelic Bulletin: Poll Shows Support for Psilocybin in the UK; Psychedelics-tinged ETF Launches on NYSE; Patents Make Headlines